Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1814, Issue 1, 2011, Pages 161-167

  Neunzig, Ina ^a   Drǎgan, Cǎlin Aurel ^a   Widjaja, Maria ^a   Schwaninger, Andrea E ^b   Peters, Frank T ^b,c   Maurer, Hans H ^b   Bureik, Matthias ^a  

^a PomBioTech GmbH   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Adverse drug reactions; Cytochrome P450; Hepatocellular carcinoma; Whole cell biotransformation

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; CYTOCHROME P450 INHIBITOR; ECONAZOLE; ENZYME VARIANT; LUCIFERIN; MICONAZOLE; OXIDE; PRASTERONE; SORAFENIB; TESTOSTERONE;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; IC 50; NONHUMAN; PRIORITY JOURNAL; STEROID HYDROXYLATION; YEAST CELL;

ARYL HYDROCARBON HYDROXYLASES; BENZENESULFONATES; BIOCATALYSIS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECONAZOLE; FIREFLY LUCIFERIN; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOENZYMES; LIVER; MASS SPECTROMETRY; MICONAZOLE; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PYRIDINES; SCHIZOSACCHAROMYCES; TESTOSTERONE;

SCHIZOSACCHAROMYCETACEAE;

EID: 78649451800     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.07.011     Document Type: Article

References (74)

1. K. Ruckpaul Early years of cytochrome P450 research in Berlin-Buch: its present state and origin of the biochemical and biophysical conferences Biochem. Biophys. Res. Commun. 312 2003 65 74
2. R. Bernhardt Cytochromes P450 as versatile biocatalysts J. Biotechnol. 124 2006 128 145
3. D. Kim, and F.P. Guengerich Cytochrome P450 activation of arylamines and heterocyclic amines Annu. Rev. Pharmacol. Toxicol. 45 2005 27 49
4. F. Hannemann, A. Bichet, K.M. Ewen, and R. Bernhardt Cytochrome P450 systems-biological variations of electron transport chains Biochim. Biophys. Acta 1770 2006 330 344
5. D.R. Nelson The cytochrome p450 homepage Hum. Genomics 4 2009 59 65
6. M. Ingelman-Sundberg Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol. Sci. 25 2004 193 200
7. C. Ioannides, Cytochromes P450-role in the metabolism and toxicity of drugs and other xenobioteics 2008 Royal Society of Chemistry Cambridge
8. D.J. Greenblatt, P. He, L. von Moltke, and M.H. Court The CYP3 Family C. Ioannides, Cytochromes P450: role in the metabolism and toxicity of drugs and other xenobiotics 2008 RSC Publishing Cambridge, UK 354 383
9. T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, V. Fischer, R. Tyndale, T. Inaba, W. Kalow, and H.V. Gelboin Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine J. Biol. Chem. 264 1989 10388 10395
10. T. Tateishi, M. Watanabe, H. Moriya, S. Yamaguchi, T. Sato, and S. Kobayashi No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins Biochem. Pharmacol. 57 1999 935 939
11. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P.B. Watkins, A. Daly, S.A. Wrighton, S.D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M.S. Boguski, and E. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 27 2001 383 391
12. A. Westlind, S. Malmebo, I. Johansson, C. Otter, T.B. Andersson, M. Ingelman-Sundberg, and M. Oscarson Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43 Biochem. Biophys. Res. Commun. 281 2001 1349 1355 (Pubitemid 32924568)
13. V. Agarwal, R.P. Kommaddi, K. Valli, D. Ryder, T.M. Hyde, J.E. Kleinman, H.W. Strobel, and V. Ravindranath Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite PLoS ONE 3 2008 e2337
14. I. Bieche, C. Narjoz, T. Asselah, S. Vacher, P. Marcellin, R. Lidereau, P. Beaune, and I. de Waziers Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues Pharmacogenet. Genomics 17 2007 731 742
15. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate J. Biol. Chem. 262 1987 13534 13537 (Pubitemid 17144304)
16. J. Marill, T. Cresteil, M. Lanotte, and G.G. Chabot Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites Mol. Pharmacol. 58 2000 1341 1348
17. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, and Y. Kanakubo Significance of cytochrome P-450 (P-450 HFLa) of human fetal livers in the steroid and drug oxidations Biochem. Pharmacol. 36 1987 453 456
18. R.N. Hines The ontogeny of drug metabolism enzymes and implications for adverse drug events Pharmacol. Ther. 118 2008 250 267
19. M. Kitada, T. Kamataki, K. Itahashi, T. Rikihisa, R. Kato, and Y. Kanakubo Immunochemical examinations of cytochrome P-450 in various tissues of human fetuses using antibodies to human fetal cytochrome P-450, P-450 HFLa Biochem. Biophys. Res. Commun. 131 1985 1154 1159
20. D. Lacroix, M. Sonnier, A. Moncion, G. Cheron, and T. Cresteil Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth Eur. J. Biochem. 247 1997 625 634
21. J.M. Treluyer, E. Rey, M. Sonnier, G. Pons, and T. Cresteil Evidence of impaired cisapride metabolism in neonates Br. J. Clin. Pharmacol. 52 2001 419 425
22. S. Bernardini, D.S. Semama, F. Huet, C. Sgro, and J.B. Gouyon Effects of cisapride on QTc interval in neonates Arch. Dis. Child. Fetal Neonatal Ed. 77 1997 F241 F243
23. O. Burk, H. Tegude, I. Koch, E. Hustert, R. Wolbold, H. Glaeser, K. Klein, M.F. Fromm, A.K. Nuessler, P. Neuhaus, U.M. Zanger, M. Eichelbaum, and L. Wojnowski Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine J. Biol. Chem. 277 2002 24280 24288
24. S.C. Sim, R.J. Edwards, A.R. Boobis, and M. Ingelman-Sundberg CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele Pharmacogenet. Genomics 15 2005 625 631
25. P. Smit, R.H. van Schaik, M. van der Werf, A.W. van den Beld, J.W. Koper, J. Lindemans, H.A. Pols, A.O. Brinkmann, F.H. de Jong, and S.W. Lamberts A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels J. Clin. Endocrinol. Metab. 90 2005 5313 5316
26. C. Rodriguez-Antona, M. Jande, A. Rane, and M. Ingelman-Sundberg Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers Clin. Pharmacol. Ther. 77 2005 259 270
27. J.S. Leeder, R. Gaedigk, K.A. Marcucci, A. Gaedigk, C.A. Vyhlidal, B.P. Schindel, and R.E. Pearce Variability of CYP3A7 expression in human fetal liver J. Pharmacol. Exp. Ther. 314 2005 626 635
28. C. Rodriguez-Antona, M. Axelson, C. Otter, A. Rane, and M. Ingelman-Sundberg A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1 J. Biol. Chem. 280 2005 28324 28331
29. N. Kondoh, T. Wakatsuki, A. Ryo, A. Hada, T. Aihara, S. Horiuchi, N. Goseki, O. Matsubara, K. Takenaka, M. Shichita, K. Tanaka, M. Shuda, and M. Yamamoto Identification and characterization of genes associated with human hepatocellular carcinogenesis Cancer Res. 59 1999 4990 4996
30. D. Downie, M.C.E. McFadyen, P.H. Rooney, M.E. Cruickshank, D.E. Parkin, I.D. Miller, C. Telfer, W.T. Melvin, and G.I. Murray Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers Clin. Cancer Res. 11 2005 7369 7375
31. S.R. Miranda, and S.A. Meyer Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7 Food Chem. Toxicol. 45 2007 871 877
32. R. Tsunedomi, N. Iizuka, Y. Hamamoto, S. Uchimura, T. Miyamoto, T. Tamesa, T. Okada, N. Takemoto, M. Takashima, K. Sakamoto, K. Hamada, H. Yamada-Okabe, and M. Oka Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma Int. J. Oncol. 27 2005 661 667
33. T. Kamataki, H. Hashimoto, M. Shimoji, S. Itoh, K. Nakayama, K. Hattori, T. Yokoi, M. Katsuki, and S. Aizawa Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice Toxicol. Lett. 82-83 1995 879 882
34. M.T. Granfors, J.S. Wang, L.I. Kajosaari, J. Laitila, P.J. Neuvonen, and J.T. Backman Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro Basic Clin. Pharmacol. Toxicol. 98 2006 79 85
35. D.M. Stresser, M.I. Broudy, T. Ho, C.E. Cargill, A.P. Blanchard, R. Sharma, A.A. Dandeneau, J.J. Goodwin, S.D. Turner, J.C. Erve, C.J. Patten, S.S. Dehal, and C.L. Crespi Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible Drug Metab. Dispos. 32 2004 105 112
36. P. Myllynen, M. Pasanen, and K. Vahakangas The fate and effects of xenobiotics in human placenta Expert Opin. Drug Metab. Toxicol. 3 2007 331 346
37. H. Wang, J. Ping, R.X. Peng, J. Yue, X.Y. Xia, Q.X. Li, R. Kong, and J.Y. Hong Changes of multiple biotransformation phase I and phase II enzyme activities in human fetal adrenals during fetal development Acta Pharmacol. Sin. 29 2008 231 238
38. F.M. Buratti, C. Leoni, and E. Testai Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides Toxicol. Lett. 167 2006 245 255
39. H. Hashimoto, T. Nakagawa, T. Yokoi, M. Sawada, S. Itoh, and T. Kamataki Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins Cancer Res. 55 1995 787 791
40. H. Nakamura, N. Torimoto, I. Ishii, N. Ariyoshi, H. Nakasa, S. Ohmori, and M. Kitada CYP3A4 and CYP3A7-mediated carbamazepine 10, 11-epoxidation are activated by differential endogenous steroids Drug Metab. Dispos. 31 2003 432 438
41. E. Inoue, Y. Takahashi, Y. Imai, and T. Kamataki Development of bacterial expression system with high yield of CYP3A7, a human fetus-specific form of cytochrome P450 Biochem. Biophys. Res. Commun. 269 2000 623 627
42. E.M. Gillam, R.M. Wunsch, Y.F. Ueng, T. Shimada, P.E. Reilly, T. Kamataki, and F.P. Guengerich Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase Arch. Biochem. Biophys. 346 1997 81 90
43. D.H. Kim, K.H. Kim, E.M. Isin, F.P. Guengerich, H.Z. Chae, T. Ahn, and C.H. Yun Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli Protein Expr. Purif. 57 2008 188 200
44. F.T. Peters, C.A. Dragan, D.R. Wilde, M.R. Meyer, J. Zapp, M. Bureik, and H.H. Maurer Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone Biochem. Pharmacol. 74 2007 511 520
45. S. Yamazaki, K. Sato, K. Suhara, M. Sakaguchi, K. Mihara, and T. Omura Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s J. Biochem. 114 1993 652 657
46. T. Yasumori, L.S. Chen, Q.H. Li, M. Ueda, T. Tsuzuki, J.A. Goldstein, R. Kato, and Y. Yamazoe Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19 Biochem. Pharmacol. 57 1999 1297 1303
47. A. Zollner, C.A. Dragan, D. Pistorius, R. Muller, H.B. Bode, F.T. Peters, H.H. Maurer, and M. Bureik Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid Biol. Chem. 390 2009 313 317
48. F.T. Peters, C.A. Dragan, A.E. Schwaninger, C. Sauer, J. Zapp, M. Bureik, and H.H. Maurer Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine Forensic Sci. Int. 184 2009 69 73
49. F.T. Peters, C.A. Dragan, A. Kauffels, A.E. Schwaninger, J. Zapp, M. Bureik, and H.H. Maurer Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6-a versatile alternative to multistep chemical synthesis J. Anal. Toxicol. 33 2009 190 197
50. T. Hakki, and R. Bernhardt CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets Pharmacol. Ther. 111 2006 27 52
51. T. Hakki, S. Zearo, C.A. Dragan, M. Bureik, and R. Bernhardt Coexpression of redox partners increases the hydrocortisone (cortisol) production efficiency in CYP11B1 expressing fission yeast Schizosaccharomyces pombe J. Biotechnol. 133 2008 351 359
52. M. Bureik, K. Hübel, C.-A. Dragan, J. Scher, H. Becker, N. Lenz, and R. Bernhardt Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11b-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension Mol. Cell. Endocrinol. 217 2004 249 254
53. M. Bureik, B. Schiffler, Y. Hiraoka, F. Vogel, and R. Bernhardt Functional expression of human mitochondrial CYP11B2 in fission yeast and identification of a new internal electron transfer protein, etp1 Biochemistry 41 2002 2311 2321
54. J.R. Sambrook, and D.W. Molecular cloning: a laboratory manual 2001 CSHL Press Woodbury
55. C.A. Dragan, S. Zearo, F. Hannemann, R. Bernhardt, and M. Bureik Efficient conversion of 11-deoxycortisol to cortisol (hydrocortisone) by recombinant fission yeast Schizosaccharomyces pombe FEMS Yeast Res. 5 2005 621 625
56. C. Alfa, and Cold Spring Harbor Laboratory Experiments with fission yeast : a laboratory course manual 1993 Cold Spring Harbor Laboratory Press Plainview, N.Y.
57. K. Maundrell Thiamine-repressible expression vectors pREP and pRIP for fission yeast Gene 123 1993 127 130
58. K. Maundrell nmt1 of fission yeast. A highly transcribed gene completely repressed by thiamine J. Biol. Chem. 265 1990 10857 10864
59. A. Zollner, M.K. Parr, C.A. Dragan, S. Dras, N. Schlorer, F.T. Peters, H.H. Maurer, W. Schanzer, M. Bureik, CYP21-catalyzed production of the long-term urinary metandienone metabolite 17beta-hydroxymethyl-17 alpha-methyl-18- norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping, Biol. Chem. 391 (2010) 119-127.
60. M. Suga, and T. Hatakeyama A rapid and simple procedure for high-efficiency lithium acetate transformation of cryopreserved Schizosaccharomyces pombe cells Yeast 22 2005 799 804
61. S. Crettol, J.P. Venetz, M. Fontana, J.D. Aubert, M. Pascual, and C.B. Eap CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients Ther. Drug Monit. 30 2008 689 699
62. K. Bacsi, J. Kosa, A. Lazary, B. Balla, H. Horvath, I. Takacs, Z. Nagy, G. Speer, and P. Lakatos Impact of CYP3A7*1C polymorphism on bone mineral content in postmenopausal women Orv. Hetil. 148 2007 1273 1280
63. K. Bacsi, J.P. Kosa, G. Borgulya, B. Balla, A. Lazary, Z. Nagy, C. Horvath, G. Speer, and P. Lakatos CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women Calcif. Tissue Int. 80 2007 154 159
64. M.O. Goodarzi, N. Xu, and R. Azziz Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome J. Clin. Endocrinol. Metab. 93 2008 2909 2912
65. R.J. Bertz, and G.R. Granneman Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin. Pharmacokinet. 32 1997 210 258
66. N. Torimoto, I. Ishii, K. Toyama, M. Hata, K. Tanaka, H. Shimomura, H. Nakamura, N. Ariyoshi, S. Ohmori, and M. Kitada Helices F-G are important for the substrate specificities of CYP3A7 Drug Metab. Dispos. 35 2007 484 492
67. T. Pajic, M. Vitas, D. Zigon, A. Pavko, S.L. Kelly, and R. Komel Biotransformation of steroids by the fission yeast Schizosaccharomyces pombe Yeast 15 1999 639 645
68. J.C. Stevens, R.N. Hines, C. Gu, S.B. Koukouritaki, J.R. Manro, P.J. Tandler, and M.J. Zaya Developmental expression of the major human hepatic CYP3A enzymes J. Pharmacol. Exp. Ther. 307 2003 573 582
69. K.A. Usmani, R.L. Rose, and E. Hodgson Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals Drug Metab. Dispos. 31 2003 384 391
70. M. Ayub, and M.J. Levell The inhibition of human prostatic aromatase activity by imidazole drugs including ketoconazole and 4-hydroxyandrostenedione Biochem. Pharmacol. 40 1990 1569 1575
71. T. Sakaeda, K. Iwaki, M. Kakumoto, M. Nishikawa, T. Niwa, J.S. Jin, T. Nakamura, K. Nishiguchi, N. Okamura, and K. Okumura Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs J. Pharm. Pharmacol. 57 2005 759 764
72. E.S. Perloff, A.K. Mason, S.S. Dehal, A.P. Blanchard, L. Morgan, T. Ho, A. Dandeneau, R.M. Crocker, C.M. Chandler, N. Boily, C.L. Crespi, and D.M. Stresser Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design Xenobiotica 39 2009 99 112
73. C.A. Dragan, R.W. Hartmann, and M. Bureik A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21 J. Enzyme Inhib. Med. Chem. 21 2006 547 556
74. C. Lathia, J. Lettieri, F. Cihon, M. Gallentine, M. Radtke, and P. Sundaresan Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother. Pharmacol. 57 2006 685 692